Abstract: A combined bio-artificial liver support system, includes branch tubes that are connected in sequence: a blood input branch tube, an upstream tail end of which is set as a blood input end, a first plasma separation branch tube comprising at least a first plasma separator, a non-biological purification branch tube comprising at least a plasma perfusion device and a bilirubin adsorber, a biological purification branch tube comprising at least a hepatocyte culture cartridge assembly, and a plasma return branch tube, a downstream tail end of which is set as a blood output end.

Abstract: A combined bio-artificial liver support system, includes branch tubes that are connected in sequence: a blood input branch tube, an upstream tail end, a first plasma separation branch tube comprising at least a first plasma separator, a non-biological purification branch tube comprising at least a plasma perfusion device and a bilirubin adsorber, a biological purification branch tube comprising at least a hepatocyte culture cartridge assembly, and a plasma return branch tube, a downstream tail end of which is set as a blood output end.

Abstract: A high-fidelity AsCpf1 mutant is obtained by performing a mutation on arginine at position 951 and/or 955 of a AsCpf1 protein amino acid sequence and replacing the same with an amino acid free of forming a hydrogen bond with DNA of a target site; and the amino acid sequence thereof is shown in SEQ ID NOS: 1-3. The encoding gene of the AsCpf1 mutant has a nucleotide sequence as shown in SEQ ID NO: 4 and can be used in the construction of a CRISPR/AsCpf1 gene editing system. A CRISPR/AsCpf1 gene editing system includes a gene encoding a AsCpf1 protein, and the AsCpf1 protein is the AsCpf1 mutant mentioned above. The CRISPR/AsCpf1 gene editing system can be used in lowering an off-target effect of gene editing. The novel AsCpf1 mutant not only retains the gene editing efficiency of wild-type AsCpf1, but also has a higher specificity than the wild-type AsCpf1.

Abstract: The present application relates to a use of a nitric oxide synthase pathway inhibitor in preparation of a medicine, wherein the medicine is used for preventing, relieving and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject. The present application further relates to a use of nitric oxide synthase for screening a medicine, wherein the medicine is used for preventing, relieving and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject. The present application further relates to a pharmaceutical composition containing the nitric oxide synthase pathway inhibitor and a method for preventing, relieving and/or treating gastrointestinal ischemia-reperfusion related distal injury in a subject.

Abstract: Provided are 1,4-diphenyl-1H-imidazole and 2,4-diphenylthiazole derivatives having a structure represented by Formula I, a preparation method therefor and uses thereof: wherein R1 is any one of H, OH, and OCH3, R2 is any one of H, NO2, CH3, CF3, SO2CH3, COOCH3, or CONHCH3, R3 is any one of H, NO2, OCH3, or CF3, R4 is selected from H, CF3, or Cl, R5 is any one of H, Cl, CF3, or NHCH3, and R6 is any one of OCF3, CF3, or CN; V is either C or N, W is either CH or N, X is a C atom, Y is either CH or N, and Z is either CH or S. This compound can be used in preparation of anti-inflammatory adjuvants, TLR1 or TLR2 agonists, and anti-tumor agents and for regulating the activity activation level of TLR1 and TLR2 alkaline phosphatases in vitro and in vivo.

Abstract: The invention discloses a micromolecule polypeptide and use thereof. The micromolecule polypeptide KP-6T has a function of significantly inhibiting and reversing kidney tissue fibrosis and CKD progress without obvious toxic and side effects, so that it can be used for manufacturing a medicament for effectively inhibiting the CKD progress. Compared with a micromolecule polypeptide KP-6 disclosed in the prior art, both the KP-6T and the KP-6 can delay kidney tissue fibrosis progress of an advanced UUO mouse, however, the KP-6T contains only 11 amino acids, and has the advantage of shorter peptide chain, easier synthesis, lower cost and easier absorption and distribution in vivo.

Abstract: A combined bio-artificial liver support system, includes branch tubes that are connected in sequence: a blood input branch tube, an upstream tail end, a first plasma separation branch tube comprising at least a first plasma separator, a non-biological purification branch tube comprising at least a plasma perfusion device and a bilirubin adsorber, a biological purification branch tube comprising at least a hepatocyte culture cartridge assembly, and a plasma return branch tube, a downstream tail end of which is set as a blood output end.

Abstract: Provided are 1,4-diphenyl-1H-imidazole and 2,4-diphenylthiazole derivatives having a structure represented by Formula I, a preparation method therefor and uses thereof: wherein R1 is any one of H, OH, and OCH3, R2 is any one of H, NO2, CH3, CF3, SO2CH3, COOCH3, or CONHCH3, R3 is any one of H, NO2, OCH3, or CF3, R4 is selected from H, CF3, or Cl, R5 is any one of H, Cl, CF3, or NHCH3, and R6 is any one of OCF3, CF3, or CN; V is either C or N, W is either CH or N, X is a C atom, Y is either CH or N, and Z is either CH or S. This compound can be used in preparation of anti-inflammatory adjuvants, TLR1 or TLR2 agonists, and anti-tumor agents and for regulating the activity activation level of TLR1 and TLR2 alkaline phosphatases in vitro and in vivo.

Abstract: A method of preparing a crystalline contrast agent for magnetic resonance imaging from a zwitterionic carboxylic pyridyl ligand includes mixing metal ion and the pyridyl ligand and obtaining crystals therefrom. The crystalline contrast agent includes a manganese-organic or gadolinium-organic 3D framework. The crystalline contrast agent is employed in a kit and a pharmaceutically acceptable composition. The method allows for preparing crystalline contrast agents with superior properties with easily available starting materials and with an economic and efficient process. The method allows for preparing crystalline contrast agents with exceptional water-stability and water-solubility, which exhibit high longitudinal relaxivities and with excellent stabilities under physiological conditions and low cytotoxicity. Further provided is a method for in vivo imaging of a subject, in particular a human, comprising administering the crystalline contrast agent to the subject.

Abstract: P2Y1 receptor and an antagonist thereof are used in anti-depression and/or anti-anxiety disorder. It has been verified through experimental studies that the P2Y1 receptor can be used for screening for a medicine of anti-depression and/or anti-anxiety disorder, and also used for screening for depression and/or anxiety disorder, and for early warning of depression and/or anxiety disorder; and the antagonist of P2Y1 receptor has anti-depression and anti-anxiety effects which can be used to prepare a medicine of anti-depression and/or anti-anxiety disorder.

Abstract: A method of preparing a crystalline copper-based coordination polymer comprises preparing a mixture of copper ions and a first quaternized carboxylate pyridyl ligand; adding a second polypyridyl ligand; and forming crystals of a copper-based coordination polymer therefrom. The crystalline copper-based coordination polymer is suitable for providing a sensing platform for detecting the presence of one or more target nucleic acid sequences such as viral RNA, in particular Dengue virus and/or Zika virus RNA with high selectivity and high specificity. A method of detecting at least a first target nucleic acid sequence, in particular from a viral RNA, in particular it is Flavivirus RNA, in a sample is also provided. Further provided is a kit including the crystalline copper-based coordination polymer and an oligonucleotide probe.

Abstract: A construction method for an immunodeficient rat model includes the following steps. The gRNAs targeted for knocking out a Prkdc gene and an IL2R? gene are mixed with CAS9 mRNA respectively, and frozen in RNase-free ultrapure water to obtain injections A and B correspondingly. A human SIRP? genomic DNA is amplified, purified, and frozen in RNase-free ultrapure water to obtain an injection C. The injections A and B are injected into cytoplasm of fertilized eggs of different rats, and the injection C is injected into a pronucleus of a fertilized egg of another rat. The three fertilized eggs are then transplanted into different pseudo-pregnant female rats to breed second-generation rats A, B and C, respectively. The second-generation rats A, B and C are intercrossed to breed an F1 generation; and the F1 generation is further intercrossed to obtain IL2R? and Prkdc gene knockout immunodeficient rat models with human SIRP? gene.

Abstract: The present invention provides use of penta-substituted tetrahydropyrimidines in preparation of thermo-sensitive fluorescent materials. Said penta-substituted tetrahydropyrimidine compounds have linear temperature dependence of red-edge excitation wavelength (LTDREEW). When different excitation wavelengths are chosen, such compounds present fluorescence color and/or fluorescence on-off switch in different temperature ranges. Also their fluorescence intensity ratios or fluorescence intensities exhibit good linear relation or power function relation to temperature, which can be used as the thermo-sensitive fluorescent materials with high sensitivity and wide temperature range (0-450 K).

Abstract: The present invention relates in a first aspect to a method of preparing a crystalline lanthanum-carboxylate coordination polymer and the crystalline lanthanum-carboxylate coordination polymer obtained or obtainable by the method. In another aspect of the present invention, also provides a method of detecting a target nucleic acid sequence in a sample.

Abstract: A support unit (200), a support device (100) and an emission tomography device using the support device (100) are provided. The support unit (200) comprises: a support body (210), in which an accommodation space (220) that penetrates through the support body is provided, comprising multiple support positions (230A, 230B) that are distributed along a circumferential direction of the accommodation space (220); and multiple fastening means (240A, 240B), connected to at least some of the multiple support positions. At least some of the multiple fastening means (240A, 240B) can move between a contraction position and an extension position along a radial direction of the accommodation space (220). The fastening means (240A, 240B) are used to fasten detectors of the emission tomography device.

Abstract: A method of preparing a crystalline zwitterionic zinc(II)-carboxylate compound includes the steps of preparing a mixture of zinc(II) ions and a first pyridyl ligand having three carboxylic acid moieties; subjecting the mixture to conditions under which a precipitate is formed; separating the precipitate; adding a solvent and optionally a second pyridyl ligand to the separated precipitate; subjecting the obtained mixture to conditions under which crystals of the zwitterionic zinc(II)-carboxylate compound are formed; and separating the crystals of the zwitterionic zinc(II)-carboxylate compound. Preferably but not exclusively, the crystalline zwitterionic zinc(II)-carboxylate compound essentially consists of at least one 1D coordination polymer.

Abstract: The present invention discloses a short peptide targeting EPS8 binding with EGFR and use thereof, and sequence of the short peptide is N?-Arg-Lys-Lys-Asn-Lys-Pro-Pro-Pro-Pro-Lys-Lys-C?. The short peptide can effectively inhibit proliferation of EPS8 positive tumors, and can also be used to make a pharmaceutical preparation for treating EPS8 positive tumors, which has the potential of being developed into anti-cancer peptide inhibitor drugs.

Abstract: A support unit (200), a support device (100) and an emission tomography device using the support device (100) are provided. The support unit (200) comprises: a support body (210), in which an accommodation space (220) that penetrates through the support body is provided, comprising multiple support positions (230A, 230B) that are distributed along a circumferential direction of the accommodation space (220); and multiple fastening means (240A, 240B), connected to at least some of the multiple support positions. At least some of the multiple fastening means (240A, 240B) can move between a contraction position and an extension position along a radial direction of the accommodation space (220). The fastening means (240A, 240B) are used to fasten detectors of the emission tomography device.

Abstract: The present invention provides use of penta-substituted tetrahydropyrimidines in preparation of thermo-sensitive fluorescent materials. Said penta-substituted tetrahydropyrimidine compounds have linear temperature dependence of red-edge excitation wavelength (LTDREEW). When different excitation wavelengths are chosen, such compounds present fluorescence color and/or fluorescence intensity on-off switching in different temperature ranges. Also their fluorescence intensity ratios or fluorescence intensities exhibit good linear relation or power function relation to temperature, which can be used as the thermo-sensitive fluorescent materials with high sensitivity and wide temperature range (0-450 K).

Abstract: The present invention discloses a short peptide targeting EPS8 binding with EGFR and use thereof, and sequence of the short peptide is N?-Arg-Lys-Lys-Asn-Lys-Pro-Pro-Pro-Pro-Lys-Lys-C?. The short peptide can effectively inhibit proliferation of EPS8 positive tumors, and can also be used to make a pharmaceutical preparation for treating EPS8 positive tumors, which has the potential of being developed into anti-cancer peptide inhibitor drugs.